Inositol: Tolerability and Side Effects in Studies

In clinical studies, myo-inositol is generally described as well tolerated, and the most commonly reported adverse effects involve the gastrointestinal tract. These include nausea, bloating or flatulence, and diarrhea.

However, “well tolerated” does not mean “free of side effects.” Safety was not the primary endpoint in many studies, adverse events were reported inconsistently, and rare reactions are difficult to detect in small, short trials.

What does tolerability mean in a clinical study?

Tolerability describes how easily participants can follow a protocol without symptoms that make them reduce the dose, miss doses, or withdraw. It is not the same as complete safety.

Someone may experience mild gastrointestinal discomfort yet continue taking a supplement. Conversely, a rare serious adverse event may simply not occur in a sample of a few dozen or a few hundred participants.

Which side effects were reported most often?

A dedicated 2011 review of inositol safety identified the most common adverse effects at high experimental doses as nausea, flatulence, and diarrhea.

These symptoms were generally described as mild. However, the review drew on a limited number of clinical studies, some small and conducted in specific populations.

What did the 2011 safety review show?

Carlomagno and Unfer summarized the evidence available at that time on inositol tolerability, including studies using substantially higher doses than most modern metabolic trials.

The authors found no obvious sharp deterioration in tolerability with increasing doses, and typical complaints remained predominantly gastrointestinal.

Nevertheless, this does not mean high experimental doses are proven safe for self-administration. The available evidence comes from small, short-duration trials.

What did the 2024 systematic review add?

The systematic review by Fitz et al. included 30 trials and 2,230 participants. It assessed adverse events as well as efficacy.

An important limitation is that gastrointestinal adverse-event data were available for only some included studies, while other adverse-event types were reported even less frequently. Thus, safety reporting was incomplete.

In studies comparing myo-inositol with metformin, gastrointestinal complaints occurred less often on average in the inositol groups. However, this is a comparison with a specific active medication, not evidence that inositol itself causes no side effects.

Why does “fewer side effects than metformin” not mean “no side effects”?

If one group has fewer gastrointestinal complaints than another, this only demonstrates relative tolerability in that particular study.

For example, both interventions may cause discomfort, but one does so less frequently and therefore has a better tolerability profile in that comparison. Its adverse-event rate is not zero.

What is known about high experimental doses?

Older psychiatric studies used 12–18 g of inositol daily. In these small studies, side effects were generally described as mild.

For example, a crossover study in panic disorder gradually increased the inositol dose to 18 g per day. Only 20 participants were included.

Such evidence is useful for understanding the history of tolerability research, but not for developing an everyday dosing regimen. A small sample cannot reliably rule out rare adverse events.

What is known about doses commonly studied today?

Many modern clinical studies used myo-inositol at doses of several grams per day. These studies have not shown a consistent, specific signal of serious harm.

However, this wording has an important limitation: the absence of a consistent signal does not prove that rare or long-term risks are entirely absent.

What do studies in pregnant women tell us?

Myo-inositol has also been studied during pregnancy. Some randomized trials did not report serious adverse reactions attributed to the studied intervention.

In the PONTI pilot trial, no adverse pregnancy events were recorded that the authors attributed to inositol use.

However, pregnancy is a distinct clinical situation. The lack of an obvious signal in a few studies does not justify a universal conclusion about the safety of any supplement during pregnancy.

Why does a lack of reported side effects not prove that none exist?

A study may fail to report an adverse event for several reasons: it did not occur, it was not systematically collected, it was not considered related to the intervention, or the sample was too small for it to appear.

This is particularly relevant to rare reactions. If an event occurs in one person out of several thousand, a study with 100 participants has very little chance of detecting it.

What is known about long-term safety?

Most clinical studies of inositol last from several weeks to several months. Longer studies exist, but they are far fewer.

Therefore, confidence in short- and medium-term tolerability is greater than confidence in conclusions about very prolonged continuous use.

This does not mean long-term use is necessarily unsafe. It means less evidence is available to support strong claims.

Which adverse events were reported in studies?

When should you stop self-administering and consult a doctor?

• if pronounced or persistent adverse symptoms develop after starting use;
• if you have chronic conditions or take medicines at the same time;
• if use is planned during pregnancy or breastfeeding;
• if a reaction develops that cannot readily be explained by ordinary short-term gastrointestinal discomfort;
• if you are considering independently reproducing the high doses used in older clinical studies.

Frequently asked questions

What side effects of inositol are reported most often?
Mild gastrointestinal symptoms are mentioned most frequently: nausea, flatulence, bloating, and diarrhea.

Can we say that inositol has no side effects?
No. It was generally well tolerated in studies, but adverse events were not reported equally thoroughly in every study.

Were high doses of 12–18 g shown to be safe?
These doses were used in older, small psychiatric studies and mainly caused mild reactions, but this does not establish their safety for unsupervised use.

Why does it matter whether a study specifically collected side-effect data?
If safety is not a prespecified outcome, some mild or rare reactions may be underestimated.

Are there data on inositol safety during pregnancy?
Some clinical studies in pregnant women found no obvious specific signal of serious harm, but this is not enough for a universal conclusion. Supplement use during pregnancy should be discussed with a doctor.

Is inositol well tolerated with long-term use?
Studies lasting several months or longer exist, but the long-term evidence base is smaller than that for short- and medium-term use. Confidence in very prolonged continuous use is therefore lower.

What should I do if unwanted symptoms occur after starting use?
Do not ignore pronounced or persistent reactions. Stop using it on your own and discuss the symptoms with a doctor, especially if you have other medical conditions or take medicines.

References

• Carlomagno G., Unfer V. (2011). Inositol safety: clinical evidences. European Review for Medical and Pharmacological Sciences. PubMed
• Fitz V. et al. (2024). Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. Journal of Clinical Endocrinology & Metabolism. PubMed
• Levine J. (1997). Controlled trials of inositol in psychiatry. European Neuropsychopharmacology. PubMed
• Palatnik A. et al. (2001). Double-blind, controlled, crossover trial of inositol versus fluvoxamine for panic disorder. Journal of Clinical Psychopharmacology. PubMed
• Randomized clinical study in pregnancy (2022). PubMed
• Greene N. D. E. et al. (2016). Inositol for the prevention of neural tube defects: a pilot randomised controlled trial. British Journal of Nutrition. PubMed

Dietary supplement. Not a medicinal product. Consult a doctor before use.